79 research outputs found
Oligosaccharin - A new systemic factor in the acquisition of freeze tolerance in winter plants
The acquisition of freeze tolerance in winter plants involves, among other cellular responses, activated catabolism of cell wall polysaccharides, thereby liberating oligosaccharides. One of these was identified as an oligosaccharin (physiologically active fragment) that most likely originates from hemicelluloses. Treatment of winter wheat seedlings with the oligosaccharin at 2Β°C increased their freeze tolerance by βΌ30%. Results obtained to date suggest that the oligosaccharin acts as an endogenous and systemic signaling molecule during cold adaptation. Β© 2005 SocietΓ Botanica Italiana
The effect of local immunity on gastric cancer prognosis
Aim. To study the state of local immunity in patients with gastric adenocarcinoma.
Materials and methods. From 2017 to 2018, 45 previously untreated patients with gastric adenocarcinoma (25 with stage IIII, 20 with stage IV) received surgical/combined treatment or chemotherapy, respectively, at the Blokhin Scientific Research Center of Oncology. Tumor tissue was taken before treatment. By using flow cytometry there were evaluated the percentage of tumor tissue infiltration by lymphocytes (CD45+CD14-TIL); T cells (CD3+CD19-TIL); B cells (CD3-CD19+TIL); NK cell (CD3-CD16+CD56+TIL); effector cells CD16 (CD16+Perforin+TIL) and CD8 (CD8+Perforin+TIL) with their cytotoxic potential active CD16TIL and active CD8TIL; subpopulations of regulatory T cells NKT cells (CD3+CD16+CD56+TIL), regulatory cells CD4 (CD4+CD25+CD127-TIL) and CD8 (CD8+CD11b-CD28-TIL). The prognostic value of immune cells for overall survival (OS) and progression-free survival (PFS) was assessed.
Results. A favorable prognosis factor for progression-free survival in patients with local and locally advanced forms of gastric cancer was an increase in the number of CD3-CD19+TIL (HR 0.862, 95% CI 0.7820.957, p=0.005), and an unfavorable prognosis was an increase in NK cells (CD3-CD16+CD56+TIL); HR 1.382, 95% CI 1.0871.758, p=0.008. The negative effect of the relative content of NK cells (CD3-CD16+CD56+TIL) and NKT cells (CD3+CD16+CD56+TIL) on OS of patients with metastatic gastric cancer noted (HR 1.249, 95% CI 0.9971.564, p=0.053; HR 1.127, 95% CI 1.0251.239, p=0.013). At the same time, an increase in the percentage of tumor tissue infiltration by lymphocytes (CD45+CD14-TIL) and an increase in the age of patients (HR 1.005, 95% CI 1.0021.008, p=0.003; HR 1.098, 95% CI 1.0311.170, p=0.004) reduce the incidence of PFS in patients with metastatic gastric carcinoma.
Conclusion. Indices of local immunity can serve as additional prognostic factors for gastric carcinoma
ΠΠ΅Π΄ΠΈΠΊΠΎ-ΡΠΎΡΠΈΠ°Π»ΡΠ½Π°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΈ ΡΠ°ΡΡΠ΅Ρ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±ΡΠ΅ΠΌΠ΅Π½ΠΈ Π°ΠΊΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ° Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
Objective: to assess the economic burden of ankylosing spondylitis (AS) and non-radiological axial spondyloarthritis (nr-axSpA) in the Russian Federation, as well as the availability and economic prospects for more complete provision of biological disease-modifying antirheumatic drugs (bDMARDs) to patients with AS and nr-axSpA.Patients and methods. The prevalence of AS and nr-axSpA and organizational aspects of providing with bDMARDs to this category of patients were analyzed.A variant model has been developed in Microsoft Excel, allows to calculate the indicators of the economic burden of AS and nr-axSpA in the Russian Federation, taking into account the economic losses associated with disability, as well as the low availability of bDMARDs. During study preparation, data from real clinical practice and the opinions of experts in the field of AS from various regions of the Russian Federation were studied.The economic burden was calculated as the sum of direct and indirect costs per patient and the population. Additionally, the specific economic burden per capita was determined.Results and discussion. According to expert estimates, the prevalence of AS and nr-axSpA today is 105.0 and 33.2 thousand people, respectively.The current economic burden of the AS for 2019 is estimated at 21.9 billion rubles per population, or 395.5 thousand rubles for 1 patient. The ratio of direct and indirect costs was 1:4, i.e. 4.7 billion rubles β direct costs (84.3 thousand rubles per 1 patient) and 17.2 billion rubles β indirect costs (311.2 thousand rubles per 1 patient). The burden per capita β 149 rubles.Nr-axSpA's current economic burden in 2019 reached 3.0 billion rubles, or 182.9 thousand rubles for 1 patient. The ratio of direct and indirect costs is estimated as 2:5, or 0.9 billion rubles β direct costs (53.0 thousand rubles per 1 patient) and 2.2 billion rubles β indirect costs (130.0 thousand rubles per 1 patient). The burden per capita β 21 rubles.Conclusion. The economic burden of AS and nr-axSpA can be reduced by providing patients with bDMARDs in the required amount: 15% of patients with AS and 10% with nr-axSpA. Due to the imperfection of the regulatory framework, patients with nr-axSpA experience serious difficulties in receiving this therapy within the framework of preferential drug coverage and compulsory health insurance. With the provision of bDMARDs for about 15 and 10% of patients with AS and nr-axSpA, respectively, on the horizon of 5 years, a decrease in disability by 75% and temporary disability by 60% is expected. At the same time, the economic burden for 5 years will decrease by about 40% for each nosology.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±ΡΠ΅ΠΌΠ΅Π½ΠΈ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠ° (ΠΠ‘) ΠΈ Π½Π΅ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΠΊΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ° (Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ) Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΠΈ ΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ² Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π½ΠΎ-ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠ½ΡΠΌΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ (ΠΠΠΠ) Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ ΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΡΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠΠ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
.Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° Π²Π°ΡΠΈΠ°ΡΠΈΠ²Π½Π°Ρ ΠΌΠΎΠ΄Π΅Π»Ρ Π² Microsoft Excel, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ°ΡΡΡΠΈΡΠ°ΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ Ρ ΡΡΠ΅ΡΠΎΠΌ ΠΏΠΎΡΠ΅ΡΡ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΡΡΡΠ°ΡΠΎΠΉ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ Π½ΠΈΠ·ΠΊΠΎΠΉ Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΡΡ ΠΠΠΠ.ΠΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΈΠ·ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΈ ΠΌΠ½Π΅Π½ΠΈΡ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² Π² ΠΎΠ±Π»Π°ΡΡΠΈ Π°ΠΊΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ° ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ±ΡΠ΅ΠΊΡΠΎΠ² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ.ΠΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ ΡΠ°ΡΡΡΠΈΡΡΠ²Π°Π»ΠΎΡΡ ΠΊΠ°ΠΊ ΡΡΠΌΠΌΠ° ΠΏΡΡΠΌΡΡ
ΠΈ ΠΊΠΎΡΠ²Π΅Π½Π½ΡΡ
Π·Π°ΡΡΠ°Ρ Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΈ Π½Π° ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡ Π² ΡΠ΅Π»ΠΎΠΌ. ΠΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ ΡΠ΄Π΅Π»ΡΠ½ΠΎΠ΅ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ Π½Π° Π΄ΡΡΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠΎ ΡΠΊΡΠΏΠ΅ΡΡΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠ΅, ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½Ρ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 105,0 ΠΈ 33,2 ΡΡΡ. ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΠ΅ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ ΠΠ‘ Π·Π° 2019 Π³. ΠΎΡΠ΅Π½Π΅Π½ΠΎ Π² 21,9 ΠΌΠ»ΡΠ΄ ΡΡΠ±. Π½Π° ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡ, ΠΈΠ»ΠΈ Π² 395,5 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π‘ΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΏΡΡΠΌΡΡ
ΠΈ ΠΊΠΎΡΠ²Π΅Π½Π½ΡΡ
Π·Π°ΡΡΠ°Ρ ΡΠΎΡΡΠ°Π²Π»ΡΠ»ΠΎ 1:4, Ρ. Π΅. 4,7 ΠΌΠ»ΡΠ΄ ΡΡΠ±. β ΠΏΡΡΠΌΡΠ΅ Π·Π°ΡΡΠ°ΡΡ (84,3 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°) ΠΈ 17,2 ΠΌΠ»ΡΠ΄ ΡΡΠ±. β ΠΊΠΎΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π°ΡΡΠ°ΡΡ (311,2 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°). ΠΡΠ΅ΠΌΡ Π½Π° Π΄ΡΡΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ β 149 ΡΡΠ±.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΠ΅ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ Π·Π° 2019 Π³. Π΄ΠΎΡΡΠΈΠ³Π°Π»ΠΎ 3,0 ΠΌΠ»ΡΠ΄ ΡΡΠ±. Π½Π° ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡ, ΠΈΠ»ΠΈ 182,9 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π‘ΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΏΡΡΠΌΡΡ
ΠΈ ΠΊΠΎΡΠ²Π΅Π½Π½ΡΡ
Π·Π°ΡΡΠ°Ρ ΡΠ°ΡΡΠ΅Π½Π΅Π½ΠΎ ΠΊΠ°ΠΊ 2:5, ΠΈΠ»ΠΈ 0,9 ΠΌΠ»ΡΠ΄ ΡΡΠ±. β ΠΏΡΡΠΌΡΠ΅ Π·Π°ΡΡΠ°ΡΡ (53,0 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°) ΠΈ 2,2 ΠΌΠ»ΡΠ΄ ΡΡΠ±. β ΠΊΠΎΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π°ΡΡΠ°ΡΡ (130,0 ΡΡΡ. ΡΡΠ±. Π½Π° 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°). ΠΡΠ΅ΠΌΡ Π½Π° Π΄ΡΡΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ β 21 ΡΡΠ±.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΎ Π·Π° ΡΡΠ΅Ρ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΠΠΠ Π² Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠΌ ΠΎΠ±ΡΠ΅ΠΌΠ΅: 15% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΠΠ‘ ΠΈ 10% ΠΏΡΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ. ΠΠ·-Π·Π° Π½Π΅ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²Π° Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π±Π°Π·Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ ΠΈΡΠΏΡΡΡΠ²Π°ΡΡ ΡΠ΅ΡΡΠ΅Π·Π½ΡΠ΅ ΡΡΡΠ΄Π½ΠΎΡΡΠΈ ΠΏΡΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΡΠ°ΠΌΠΊΠ°Ρ
Π»ΡΠ³ΠΎΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ°Ρ
ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠΈ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠΈ ΠΠΠΠ ΠΎΠΊΠΎΠ»ΠΎ 15 ΠΈ 10% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ‘ ΠΈ Π½Ρ-Π°ΠΊΡΠ‘ΠΏΠ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ Π½Π° Π³ΠΎΡΠΈΠ·ΠΎΠ½ΡΠ΅ 5 Π»Π΅Ρ ΠΎΠΆΠΈΠ΄Π°Π΅ΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ Π½Π° 75% ΠΈ Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΡΡΡΠ°ΡΡ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ Π½Π° 60%. ΠΡΠΈ ΡΡΠΎΠΌ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±ΡΠ΅ΠΌΡ Π·Π° 5 Π»Π΅Ρ ΡΠΌΠ΅Π½ΡΡΠΈΡΡΡ ΠΏΡΠΈΠΌΠ΅ΡΠ½ΠΎ Π½Π° 40% Π΄Π»Ρ ΠΊΠ°ΠΆΠ΄ΠΎΠΉ Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΠΈ
ΠΠ΅Π΄ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π²Π»ΠΈΡΠ½ΠΈΡ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, Π½Π° ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΡ ΡΡΡΠ°Π½Ρ Ρ ΡΡΠ΅ΡΠΎΠΌ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠ΅Π½ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠΎΡΠΌΡ
The paper presents the data of an original study evaluating the impact of disability associated with a number of rheumatic diseases (RDs) (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) on the country's economy, as well as their related losses of the state under the conditions of implementation of the upcoming pension reform (PR). The authors consider the socioeconomic importance of disability associated with RDs in the current period and after PR implementation in 2019β2028, determine the degree of its influence on the country's gross domestic product, and also calculate the economic efficiency of return of the potentially able-bodied proportion of disabled people (able-bodied population) to socioeconomic activity.The opinions of experts and leading experts in this area from different subjects of the Russian Federation were taken into account when preparing the study.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠ΅Π½ΠΊΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ ΡΡΠ΄ΠΎΠΌ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ β Π Π (ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΉ Π°ΡΡΡΠΈΡ, Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΉ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ), Π½Π° ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΡ ΡΡΡΠ°Π½Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ Π½ΠΈΠΌΠΈ ΠΏΠΎΡΠ΅ΡΡ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠ΅Π΄ΡΡΠΎΡΡΠ΅ΠΉ ΠΏΠ΅Π½ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠΎΡΠΌΡ (ΠΠ ). Π Π°ΡΡΠΌΠΎΡΡΠ΅Π½ΠΎ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ Π Π, Π² ΡΠ΅ΠΊΡΡΠ΅ΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΠ 2019β2028 Π³Π³., ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° ΡΡΠ΅ΠΏΠ΅Π½Ρ Π΅Π΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° Π²Π°Π»ΠΎΠ²ΠΎΠΉ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΠΉ ΠΏΡΠΎΠ΄ΡΠΊΡ ΡΡΡΠ°Π½Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ°ΡΡΡΠΈΡΠ°Π½Π° ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²ΠΎΠ·Π²ΡΠ°ΡΠ° ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠΉ ΡΠ°ΡΡΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² (Π»ΠΈΡ, Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΡ
ΡΡ Π² ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅) ΠΊ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ. ΠΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΡΡΡΠ΅Π½Ρ ΠΌΠ½Π΅Π½ΠΈΡ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² ΠΈ Π²Π΅Π΄ΡΡΠΈΡ
ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠΎΠ² Π² Π΄Π°Π½Π½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ±ΡΠ΅ΠΊΡΠΎΠ² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
Π ΠΠ¦ΠΠΠ’ΠΠ ΠΠΠ€ΠΠΠΠΠ D2 (DRD2) ΠΠΠΠ€ΠΠ¦ΠΠ’ΠΠ ΠΠΠ ΠΠ€ΠΠ ΠΠ§ΠΠ‘ΠΠΠ ΠΠ ΠΠΠ ΠΠΠ ΠΠΠΠΠΠ ΠΠΠ ΠΠ ΠΠΠΠΠΠ ΠΠΠ’ΠΠΠ‘ΠΠ₯ΠΠ’ΠΠ§ΠΠ‘ΠΠΠ Π’ΠΠ ΠΠΠΠ
Introduction. Despite the evolution of antipsychotic drugs, the problem of the therapy effectiveness and safety of schizophrenia spectrum disorders and comorbid conditions is very acute. The dopamine receptor D2 gene (DRD2) is one of the keyΒ targets of modern pharmacogenetic studies of mental disorders.The objective of the study was to analyze the DRD2 mRNA level in peripheral blood lymphocytes and to identify geneticΒ variations of β141Π‘ Ins/Del as potential biomarkers for antipsychotic therapy prognosis.Methods and materials. The study included 112 patients with mental disorders: 61 β with a diagnosis of schizophreniaΒ spectrum disorder, 51 β with a comorbid disease course with alcohol dependence syndrome, and 112 people as a controlΒ group. Psychometric evaluation was carried out using PANSS scale. The material was peripheral blood lymphocytes (PBLs).Β The DRD2 mRNA level was determined by real-time polymerase chain reaction with TaqMan probe. Genotyping β141Π‘Β Ins/Del was performed by the restriction fragment length polymorphism assay.Results. β141C Ins/Del DRD2 genetic variations are not associated with a risk of mental disorder development, andΒ they did not affect the DRD2 mRNA level in PBLs. There were no significant differences in the gene expression of DRD2 inΒ the control group and patients (p=0.194). Despite the improvement of the mental state in all patients included in the study,Β the studied DRD2 parameters did not affect either the mental disorder symptoms or the normalization of the patient statusΒ against the background of antipsychotic therapy. Ins/Ins genetic variation of β141C Ins/Del was significantly associatedΒ with an increase weight gain of more than 7 % on the 28th day of antipsychotic therapy.Conclusion. Ins/Ins genetic variation of β141C Ins/Del can be considered as a biomarker for the prognosis of antipsychotic-induced weight gain.Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠ²ΠΎΠ»ΡΡΠΈΡ Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΠΈ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΡ
Ρ Π½ΠΈΠΌΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ ΡΡΠΎΠΈΡ ΠΎΡΠ΅Π½Ρ ΠΎΡΡΡΠΎ. ΠΠ΅Π½ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ°Β Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π° Π2 (DRD2) β ΠΎΠ΄ΠΈΠ½ ΠΈΠ· ΠΎΠ±ΡΠ΅ΠΊΡΠΎΠ² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΠΏΡΠΈΡ
ΠΈΠ°ΡΡΠΈΠΈ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π³Π΅Π½Π° DRD2 Π² Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ
ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ (ΡΡΠΎΠ²Π½Ρ ΠΌΠ ΠΠ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² β141Π‘ Ins/Del).ΠΠ΅ΡΠΎΠ΄Ρ ΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 112 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠΌΠΈ: 61 β Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌΒ Β«Π Π°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ°Β», 51 β Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π° ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΈ 112 Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ. ΠΡΠΈΡ
ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΡΡ ΠΎΡΠ΅Π½ΠΊΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π°Β ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΊΠ°Π»Ρ PANSS. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠΌ ΡΠ»ΡΠΆΠΈΠ»ΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ (ΠΠΠ). Π£ΡΠΎΠ²Π΅Π½Ρ ΠΌΠ ΠΠ Π³Π΅Π½Π°Β DRD2 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠ¦Π Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π·ΠΎΠ½Π΄Π° TaqMan. ΠΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ β141Π‘ Ins/Del β ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π΄Π»ΠΈΠ½Ρ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ β141Π‘ Ins/Del DRD2 Π½Π΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Ρ Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΈΡ
Β ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΈ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΌΠ ΠΠ Π³Π΅Π½Π° DRD2 Π² ΠΠΠ. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½Π° DRD2 Ρ Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΈ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΈΒ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»Π°ΡΡ (Ρ=0,194). ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ DRD2 Π½Π΅ ΠΎΠΊΠ°Π·ΡΠ²Π°Π»ΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ Π½ΠΈ Π½Π° ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΡ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΈΡ
Β ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ, Π½ΠΈ Π½Π° Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΡΡΠ°ΡΡΡΠ° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΡΠΎΠ½Π΅ Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π²Π°ΡΠΈΠ°Π½ΡΒ Ins/Ins β141Π‘ Ins/Del ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π»ΡΡ Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° Π±ΠΎΠ»Π΅Π΅ 7 % Π½Π° 28-ΠΉ Π΄Π΅Π½ΡΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΠΊΠ°ΠΌΠΈ.ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π²Π°ΡΠΈΠ°Π½Ρ Ins/Ins β141Π‘ Ins/Del ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°Β Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΠΊ-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π½Π°Π±ΠΎΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π°.
ΠΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΡΡΠ°ΠΊΡΠΈΠ½Π° CBL0137 Π½Π° ΠΌΠΎΠ΄Π΅Π»ΡΡ ΠΎΡΡΡΡΡ Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠ² in vitro
Background. Curaxin CBL0137 is a novel non-genotoxic compound with anti-cancer activity based on CBL0137 ability of non-covalent interaction with DNA causing histone chaperone FACT relocation. Anti-cancer activity of this drug was demonstrated previously on the wide panel of solid cancer models in vitro and in vivo.Objectives. Estimation of anticancer effects of CBL0137 on the acute myeloblastic leukemia cells (THP-1) and acute lymphoblastic leukemia (CCRF-CEM).Materials and methods. CBL0137 cytotoxicity was analyzed using the MTT test, the effects on the cell cycle and the induction of apoptosis was assessed by flow cytometry, the activity of signaling pathways in cells treated with CBL0137 was determined by real-time polymerase chain reaction.Results. Cell treatment with CBL0137 led to cell cycle arrest and apoptosis induction. In the study of CBL0137 effect on target gene clusters of 10 signal transduction pathways involved in the pathogenesis of acute leukemia we have showed that CBL0137 inhibited the expression of down-stream genes of WNT and Hedgehog signaling in both cell lines. In THP-1 cells we also observed the inhibition of the expression of PPARΞ³ target and hypoxia-activated genes. In CCRF-CEM cells CBL0137 also induced the expression of Notch signaling target genes.Conclusion. The antitumor activity of CBL0137 was demonstrated on acute leukemia cell cultures, the drug possesses cytotoxicity, causes cell cycle arrest and activation of apoptosis. Significant changes in the expression of efferent gene clusters of several signaling pathways were observed in the cells treated with CBL0137.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΡΡΠ°ΠΊΡΠΈΠ½ CBL0137 β Π½ΠΎΠ²ΠΎΠ΅ Π½Π΅Π³Π΅Π½ΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠ΅Π΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ, Π² ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠΎΡΠΎΡΠΎΠΉ Π»Π΅ΠΆΠΈΡ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π½Π΅ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΎΠ²Π°ΡΡ Ρ ΠΠΠ, Π²ΡΠ·ΡΠ²Π°Ρ ΡΡΠ°Π½ΡΠ»ΠΎΠΊΠ°ΡΠΈΡ Π³ΠΈΡΡΠΎΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ°ΠΏΠ΅ΡΠΎΠ½Π° FACT Π² Ρ
ΡΠΎΠΌΠ°ΡΠΈΠ½ΠΎΠ²ΡΡ ΡΡΠ°ΠΊΡΠΈΡ. Π Π°Π½Π΅Π΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡΠΎΠ³ΠΎ Π°Π³Π΅Π½ΡΠ° Π±ΡΠ»Π° ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠΈΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ in vitro ΠΈ in vivo.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ CBL0137 Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΌΠΈΠ΅Π»ΠΎΠ±Π»Π°ΡΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΠΉΠΊΠΎΠ·Π° (THP-1) ΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ Π»ΠΈΠΌΡΠΎΠ±Π»Π°ΡΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΠΉΠΊΠΎΠ·Π° (CCRF-CEM) in vitro.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ CBL0137 ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΠ’Π’-ΡΠ΅ΡΡ, Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠΈΠΊΠ» ΠΈ ΠΈΠ½Π΄ΡΠΊΡΠΈΡ Π°ΠΏΠΎΠΏΡΠΎΠ·Π° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΠΈ, Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ ΠΏΡΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΠΈ Π½Π° ΠΊΠ»Π΅ΡΠΊΠΈ CBL0137 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΊΠ»Π΅ΡΠΎΠΊ CBL0137 ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ Π°ΡΠ΅ΡΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π° ΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π°ΠΏΠΎΠΏΡΠΎΠ·Π°. ΠΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ CBL0137 Π½Π° ΠΊΠ»Π°ΡΡΠ΅ΡΡ ΡΠ°ΡΠ³Π΅ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² 10 ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ, Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ
Π² ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π΅Π· ΠΎΡΡΡΡΡ
Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠ², Π΅Π³ΠΎ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΡΡΠ΅Π΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π΄Π»Ρ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ WNT ΠΈ Hedgehog Π² ΠΎΠ±Π΅ΠΈΡ
ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π»ΠΈΠ½ΠΈΡΡ
. Π ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ THP-1 ΡΠ°ΠΊΠΆΠ΅ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΡΠ΅Π½ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² PPARΞ³ ΠΈ Π³Π΅Π½ΠΎΠ², Π°ΠΊΡΠΈΠ²ΠΈΡΡΡΡΠΈΡ
ΡΡ ΠΏΡΠΈ Π³ΠΈΠΏΠΎΠΊΡΠΈΠΈ. Π ΠΊΠ»Π΅ΡΠΊΠ°Ρ
CCRF-CEM ΠΏΡΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΠΈ CBL0137, ΠΊΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΡΡΠΈΠ»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π²ΡΠ΅Ρ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ°ΡΠ³Π΅ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ Notch.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ° ΠΊΡΠ»ΡΡΡΡΠ°Ρ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΡΡΡΡ
Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠ² ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ CBL0137, ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ, Π²ΡΠ·ΡΠ²Π°Π΅Ρ Π°ΡΠ΅ΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π° ΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Π°ΠΏΠΎΠΏΡΠΎΠ·Π°. ΠΡΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΠΈ CBL0137 Π½Π°Π±Π»ΡΠ΄Π°ΡΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΊΠ»Π°ΡΡΠ΅ΡΠΎΠ² ΡΡΡΠ΅ΡΠ΅Π½ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² ΡΡΠ°Π·Ρ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ
GO-PROMTO Illuminates Protein Membrane Topologies of Glycan Biosynthetic Enzymes in the Golgi Apparatus of Living Tissues
The Golgi apparatus is the main site of glycan biosynthesis in eukaryotes. Better understanding of the membrane topology of the proteins and enzymes involved can impart new mechanistic insights into these processes. Publically available bioinformatic tools provide highly variable predictions of membrane topologies for given proteins. Therefore we devised a non-invasive experimental method by which the membrane topologies of Golgi-resident proteins can be determined in the Golgi apparatus in living tissues. A Golgi marker was used to construct a series of reporters based on the principle of bimolecular fluorescence complementation. The reporters and proteins of interest were recombinantly fused to split halves of yellow fluorescent protein (YFP) and transiently co-expressed with the reporters in the Nicotiana benthamiana leaf tissue. Output signals were binary, showing either the presence or absence of fluorescence with signal morphologies characteristic of the Golgi apparatus and endoplasmic reticulum (ER). The method allows prompt and robust determinations of membrane topologies of Golgi-resident proteins and is termed GO-PROMTO (for GOlgi PROtein Membrane TOpology). We applied GO-PROMTO to examine the topologies of proteins involved in the biosynthesis of plant cell wall polysaccharides including xyloglucan and arabinan. The results suggest the existence of novel biosynthetic mechanisms involving transports of intermediates across Golgi membranes
ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π° DRD1 (ΠΌΠ ΠΠ, Π±Π΅Π»ΠΎΠΊ) Π² Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· Π°Π½ΡΠΈΠΏΡΠΈΡ ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Introduction. There is a problem in predicting the efficacy and safety of antipsychotic therapy. Dopamine receptor D1 is one of the targets of antipsychotics. Peripheral blood lymphocytes (PBL) are the research object of neurotransmission receptors.The objective was to study DRD1 gene expression (mRNA, protein level) in PBL as a possible biomarker of olanzapine and haloperidol therapy prognosis.Methods and Materials. Sample: 106 patients diagnosed with schizophrenic spectrum disorder. Study design: prospective longitudinal follow-up with drug administration by randomization. Assessment of mental status and development of Parkinsonism: Positive and Negative Syndrome Scale (PANSS) and Simpson-Agnus Scale (SAS), respectively. PBL was study material. DRD1 mRNA level was determined by real-time PCR. DRD1 protein concentration in PBL was measured by enzyme immunoassay.Results. Haloperidol (but not olanzapine) treatment for 28 days, leads to DRD1 protein concentration decrease in PBL in a manner dependent on its initial level. DRD1 mRNA level in PBL remained unchanged during the treatment. Patients with effective therapy by olanzapine had lower DRD1 mRNA levels. Side effects of the therapy (Parkinsonism, weight gain) were not associated with studied DRD1 parameters.Conclusions. Haloperidol treatment leads to a decrease of DRD1 protein concentration in PBL, which depends on the initial protein level. Effective olanzapine therapy is associated with reduced DRD1 mRNA level in PBL before the treatment.Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π‘ΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π½ΡΠΈΠΏΡΠΈΡ
ΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, ΠΎΠ΄Π½Π° ΠΈΠ· ΠΌΠΈΡΠ΅Π½Π΅ΠΉ ΠΊΠΎΡΠΎΡΡΡ
β ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π° D1. ΠΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ (ΠΠΠ) β ΠΎΠ±ΡΠ΅ΠΊΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² Π½Π΅ΠΉΡΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠΈ.Π¦Π΅Π»Ρ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½Π° DRD1 (ΠΌΠ ΠΠ, Π±Π΅Π»ΠΎΠΊ) Π² ΠΠΠ ΠΊΠ°ΠΊ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ³ΠΎ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠ»Π°Π½Π·Π°ΠΏΠΈΠ½ΠΎΠΌ ΠΈ Π³Π°Π»ΠΎΠΏΠ΅ΡΠΈΠ΄ΠΎΠ»ΠΎΠΌ.ΠΠ΅ΡΠΎΠ΄Ρ ΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ. ΠΡΠ±ΠΎΡΠΊΠ°: 106 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Β«Π Π°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ°Β». ΠΠΈΠ·Π°ΠΉΠ½ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π»ΠΎΠ½Π³ΠΈΡΡΠ΄ΠΈΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Ρ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΏΡΡΠ΅ΠΌ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΠΈ. ΠΡΠ΅Π½ΠΊΠ° ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ°: ΡΠΊΠ°Π»Ρ ΠΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΈ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠ² (PANSS) ΠΈ Π‘ΠΈΠΌΠΏΡΠΎΠ½Π° ΠΠ³Π½ΡΡΠ° (SAS). ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΠΠ. Π£ΡΠΎΠ²Π΅Π½Ρ ΠΌΠ ΠΠ Π³Π΅Π½Π° DRD1 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π±Π΅Π»ΠΊΠ° DRD1 Π² ΠΠΠ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΠΈ Π³Π°Π»ΠΎΠΏΠ΅ΡΠΈΠ΄ΠΎΠ»Π° (Π½ΠΎ Π½Π΅ ΠΎΠ»Π°Π½Π·Π°ΠΏΠΈΠ½Π°) Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 28 Π΄Π½Π΅ΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π±Π΅Π»ΠΊΠ° DRD1 Π² ΠΠΠ ΡΠ½ΠΈΠΆΠ°Π»Π°ΡΡ Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ Π΅Π³ΠΎ Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ. Π£ΡΠΎΠ²Π΅Π½Ρ ΠΌΠ ΠΠ Π³Π΅Π½Π° DRD1 Π² ΠΠΠ ΠΎΡΡΠ°Π²Π°Π»ΡΡ Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π½ΡΠΌ ΠΏΡΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΎΠ»Π°Π½Π·Π°ΠΏΠΈΠ½ΠΎΠΌ ΠΈΠΌΠ΅Π»ΠΈ Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΠΌΠ ΠΠ DRD1. ΠΠΎΠ±ΠΎΡΠ½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌ, Π½Π°Π±ΠΎΡ Π²Π΅ΡΠ°) Π½Π΅ Π±ΡΠ»ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Ρ Ρ ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ DRD1.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΠΉΡΡΠ²ΠΈΠ΅ Π³Π°Π»ΠΎΠΏΠ΅ΡΠΈΠ΄ΠΎΠ»Π° ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π±Π΅Π»ΠΊΠ° DRD1 Π² ΠΠΠ, ΠΊΠΎΡΠΎΡΠΎΠ΅ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ Π±Π΅Π»ΠΊΠ°. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΎΠ»Π°Π½Π·Π°ΠΏΠΈΠ½ΠΎΠΌ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΌΠ ΠΠ DRD1 Π² ΠΠΠ Π΄ΠΎ Π½Π°ΡΠ°Π»Π° Π»Π΅ΡΠ΅Π½ΠΈΡ.
ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Π°Π»ΡΡΠ° ΡΠ΅ΡΠ²Π΅ΡΠ°ΡΡΠΎΠ»ΠΎΠΌ, Π³Π΅Π½ΠΈΡΡΠ΅ΠΈΠ½ΠΎΠΌ ΠΈ ΠΊΠ²Π΅ΡΡΠ΅ΡΠΈΠ½ΠΎΠΌ
Resveratrol, genistein and quercetin from the group of polyphenols from secondary plant metabolites reveal cancer preventive and antivirus effects realized via their pleiotropic influence on the different macromolecules in cells. These compounds can interact with DNA without the formation of covalent bonds. This process is usually followed by changes in spatial, physical-chemical and structural DNA characteristics that can result in disfunction of DNA metabolism enzymes and chromatin destabilization. Similar effects were described for anticancer drug Curaxine CBL0137 in association with activation of interferon-Ξ± signaling. We demonstrated dose-dependent stimulating effects of resveratrol, genistein and quercetin on interferon-Ξ± signaling using HeLa cells expressed mCherry protein with interferon-stimulated response elements (ISRE) in promoter. Furthermore, it was shown by live-cell fluorescent microscopy in HT1080 cells with mCherry-labeled histone H1.5 that described polyphenols induced the redistribution of this linker histone in cell nuclei. The data obtained suggest an existence of DNA-dependent mechanism of anticancer effects of plant polyphenols and a need for further study of crosslinks between the polyphenolsβ influence on chromatin structure and the changes in genome function, in particular, induction of interferon- interferon-Ξ± signaling.Π Π΅ΡΠ²Π΅ΡΠ°ΡΡΠΎΠ», ΠΊΠ²Π΅ΡΡΠ΅ΡΠΈΠ½ ΠΈ Π³Π΅Π½ΠΈΡΡΠ΅ΠΈΠ½, ΠΎΡΠ½ΠΎΡΡΡΠΈΠ΅ΡΡ ΠΊ ΠΏΠΎΠ»ΠΈΡΠ΅Π½ΠΎΠ»Π°ΠΌ Π²ΡΠΎΡΠΈΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠΎΠ² ΡΠ°ΡΡΠ΅Π½ΠΈΠΈΜ, ΠΎΠ±Π»Π°Π΄Π°ΡΡ Π°Π½ΡΠΈΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΠΌ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΡΠΌ ΡΡΡΠ΅ΠΊΡΠ°ΠΌΠΈ, ΡΠ΅Π°Π»ΠΈΠ·ΡΠ΅ΠΌΡΠΌΠΈ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡ
ΠΏΠ»Π΅ΠΈΜΠΎΡΡΠΎΠΏΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΈΜΡΡΠ²ΠΈΡ Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΌΠ°ΠΊΡΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ ΠΊΠ»Π΅ΡΠΊΠΈ. ΠΡΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ ΠΌΠΎΠ³ΡΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΈΜΡΡΠ²ΠΎΠ²Π°ΡΡ Ρ ΠΠΠ, Π½Π΅ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΡΠ΅ ΡΠ²ΡΠ·ΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΡΡΠ°Π½ΡΡΠ²Π΅Π½Π½ΡΡ
, ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΠΠ, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π±Π΅Π»ΠΊΠΎΠ² ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ° ΠΠΠ ΠΈ Π²ΡΠ·ΡΠ²Π°ΡΡ Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Ρ
ΡΠΎΠΌΠ°ΡΠΈΠ½Π°. Π’Π°ΠΊΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΡ Π±ΡΠ»ΠΈ ΠΎΠΏΠΈΡΠ°Π½Ρ Π΄Π»Ρ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΡΡΠ°ΠΊΡΠΈΠ½Π° CBL0137, ΠΏΡΠΈΡΠ΅ΠΌ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π΄Π°Π½Π½ΡΠΌ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ΠΌ Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Ρ
ΡΠΎΠΌΠ°ΡΠΈΠ½Π° ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΠ»Π° ΠΊ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ±. ΠΡΠΏΠΎΠ»ΡΠ·ΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ Π»ΠΈΠ½ΠΈΡ HeLa Ρ ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠΎΠΌ mCherry, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΌ Π² ΠΏΡΠΎΠΌΠΎΡΠΎΡΠ½ΠΎΠΈΜ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΡΠ½ΡΠΈΜ ΡΠ°ΠΈΜΡ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΡ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ± (ISRE), ΠΌΡ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΡΠΈΜ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠΈΜ ΡΡΡΠ΅ΠΊΡ ΡΠ΅ΡΠ²Π΅ΡΠ°ΡΡΠΎΠ»Π°, ΠΊΠ²Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΈ Π³Π΅Π½ΠΈΡΡΠ΅ΠΈΠ½Π° Π½Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ±. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΈΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎΠΈΜ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΈΜ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΠΈ Π½Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΈΜ Π»ΠΈΠ½ΠΈΠΈ HT1080 c ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΠΎ-ΠΌΠ΅ΡΠ΅Π½Π½ΡΠΌ Π³ΠΈΡΡΠΎΠ½ΠΎΠΌ H1.5 ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°ΡΡ, ΡΡΠΎ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΡΠ΅Π½ΠΎΠ»Ρ Π²ΡΠ·ΡΠ²Π°ΡΡ ΠΏΠ΅ΡΠ΅ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π»ΠΈΠ½ΠΊΠ΅ΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΡΡΠΎΠ½Π° Π² ΡΠ΄ΡΠ°Ρ
ΠΊΠ»Π΅ΡΠΎΠΊ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π½Π°ΠΌΠΈ Π΄Π°Π½Π½ΡΠ΅ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΠΠ-Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠ³ΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π΄Π΅ΠΈΜΡΡΠ²ΠΈΡ ΡΠ°ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΠΎΠ»ΠΈΡΠ΅Π½ΠΎΠ»ΠΎΠ² ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΈΜΡΠ΅Π³ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΏΠΎΠ»ΠΈΡΠ΅Π½ΠΎΠ»ΠΎΠ² Π½Π° ΡΡΡΡΠΊΡΡΡΡ Ρ
ΡΠΎΠΌΠ°ΡΠΈΠ½Π° ΠΈ ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ³ΠΎ Ρ ΡΡΠΈΠΌ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³Π΅Π½ΠΎΠΌΠ°, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ±
- β¦